Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Nov;28(5):497–507. doi: 10.1111/j.1365-2125.1989.tb03535.x

Prodrugs.

D G Waller 1, C F George 1
PMCID: PMC1380009  PMID: 2686738

Full text

PDF
497

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALBERT A. Chemical aspects of selective toxicity. Nature. 1958 Aug 16;182(4633):421–422. doi: 10.1038/182421a0. [DOI] [PubMed] [Google Scholar]
  2. Anderson J. A. Systemic absorption of topical ocularly applied epinephrine and dipivefrin. Arch Ophthalmol. 1980 Feb;98(2):350–353. doi: 10.1001/archopht.1980.01020030346024. [DOI] [PubMed] [Google Scholar]
  3. Attwood M. R., Francis R. J., Hassall C. H., Kröhn A., Lawton G., Natoff I. L., Nixon J. S., Redshaw S., Thomas W. A. New potent inhibitors of angiotensin converting enzyme. FEBS Lett. 1984 Jan 9;165(2):201–206. doi: 10.1016/0014-5793(84)80169-6. [DOI] [PubMed] [Google Scholar]
  4. Brock P. G., Jackson D. UK general practitioners experience of fenbufen in elderly patients. Eur J Rheumatol Inflamm. 1982;5(3):326–331. [PubMed] [Google Scholar]
  5. Buchanan M. R., Rosenfeld J., Hirsh J. The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo. Thromb Res. 1978 Nov;13(5):883–892. doi: 10.1016/0049-3848(78)90193-7. [DOI] [PubMed] [Google Scholar]
  6. Cairns J. A., Collins R., Fuster V., Passamani E. R. Coronary thrombolysis. Chest. 1989 Feb;95(2 Suppl):73S–87S. doi: 10.1378/chest.95.2_supplement.73s. [DOI] [PubMed] [Google Scholar]
  7. Dreyfuss J., Shaw J. M., Ross J. J., Jr Fluphenazine enanthate and fluphenazine decanoate: intramuscular injection and esterification as requirements for slow - release characteristics in dogs. J Pharm Sci. 1976 Sep;65(9):1310–1315. doi: 10.1002/jps.2600650912. [DOI] [PubMed] [Google Scholar]
  8. Duggan D. E., Hare L. E., Ditzler C. A., Lei B. W., Kwan K. C. The disposition of sulindac. Clin Pharmacol Ther. 1977 Mar;21(3):326–335. doi: 10.1002/cpt1977213326. [DOI] [PubMed] [Google Scholar]
  9. Duggan D. E., Hooke K. F., Noll R. M., Hucker H. B., Van Arman C. G. Comparative disposition of sulindac and metabolites in five species. Biochem Pharmacol. 1978;27(19):2311–2320. doi: 10.1016/0006-2952(78)90137-5. [DOI] [PubMed] [Google Scholar]
  10. Duggan D. E. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium. Drug Metab Rev. 1981;12(2):325–337. doi: 10.3109/03602538108994035. [DOI] [PubMed] [Google Scholar]
  11. Ehrnebo M., Nilsson S. O., Boréus L. O. Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man. J Pharmacokinet Biopharm. 1979 Oct;7(5):429–451. doi: 10.1007/BF01062386. [DOI] [PubMed] [Google Scholar]
  12. Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Elion G. B. Mechanism of action and selectivity of acyclovir. Am J Med. 1982 Jul 20;73(1A):7–13. doi: 10.1016/0002-9343(82)90055-9. [DOI] [PubMed] [Google Scholar]
  14. Fears R., Ferres H., Standring R. The protective effect of acylation on the stability of anisoylated plasminogen streptokinase activator complex in human plasma. Drugs. 1987;33 (Suppl 3):57–63. doi: 10.2165/00003495-198700333-00007. [DOI] [PubMed] [Google Scholar]
  15. Ferres H., Hibbs M., Smith R. A. Deacylation studies in vitro on anisoylated plasminogen streptokinase activator complex. Drugs. 1987;33 (Suppl 3):80–82. doi: 10.2165/00003495-198700333-00011. [DOI] [PubMed] [Google Scholar]
  16. Fyfe J. A., Keller P. M., Furman P. A., Miller R. L., Elion G. B. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem. 1978 Dec 25;253(24):8721–8727. [PubMed] [Google Scholar]
  17. Greb W. H., von Schrader H. W., Cerlek S., Dominis M., Hauptmann E., Zenić N. Endoscopic studies of nabumetone in patients with rheumatoid arthritis. A comparative endoscopic and histologic evaluation. Am J Med. 1987 Oct 30;83(4B):19–24. doi: 10.1016/0002-9343(87)90588-2. [DOI] [PubMed] [Google Scholar]
  18. Inturrisi C. E., Max M. B., Foley K. M., Schultz M., Shin S. U., Houde R. W. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med. 1984 May 10;310(19):1213–1217. doi: 10.1056/NEJM198405103101902. [DOI] [PubMed] [Google Scholar]
  19. Krieglstein G. K., Leydhecker W. The dose-response relationships of dipivalyl epinephrine in open-angle glaucoma. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1978 Feb 22;205(3):141–146. doi: 10.1007/BF00414393. [DOI] [PubMed] [Google Scholar]
  20. Lanza F. L., Nelson R. S., Greenberg B. P. Effects of fenbufen, indomethacin, naproxen, and placebo on gastric mucosa of normal volunteers. A comparative endoscopic and photographic evaluation. Am J Med. 1983 Oct 31;75(4B):75–79. doi: 10.1016/0002-9343(83)90332-7. [DOI] [PubMed] [Google Scholar]
  21. Leigh D. A., Reeves D. S., Simmons K., Thomas A. L., Wilkinson P. J. Talampicillin: a new derivative of ampicillin. Br Med J. 1976 Jun 5;1(6022):1378–1380. doi: 10.1136/bmj.1.6022.1378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lussier A., Tétreault L., Lebel E. Comparative study of gastrointestinal microbleeding caused by aspirin, fenbufen, and placebo. Am J Med. 1983 Oct 31;75(4B):80–83. doi: 10.1016/0002-9343(83)90333-9. [DOI] [PubMed] [Google Scholar]
  23. Nahata M. C., Powell D. A. Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate. Clin Pharmacol Ther. 1981 Sep;30(3):368–372. doi: 10.1038/clpt.1981.174. [DOI] [PubMed] [Google Scholar]
  24. Palfreyman M. G., McDonald I. A., Fozard J. R., Mely Y., Sleight A. J., Zreika M., Wagner J., Bey P., Lewis P. J. Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-beta-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase. J Neurochem. 1985 Dec;45(6):1850–1860. doi: 10.1111/j.1471-4159.1985.tb10543.x. [DOI] [PubMed] [Google Scholar]
  25. Pardridge W. M. Brain metabolism: a perspective from the blood-brain barrier. Physiol Rev. 1983 Oct;63(4):1481–1535. doi: 10.1152/physrev.1983.63.4.1481. [DOI] [PubMed] [Google Scholar]
  26. Patchett A. A., Harris E., Tristram E. W., Wyvratt M. J., Wu M. T., Taub D., Peterson E. R., Ikeler T. J., ten Broeke J., Payne L. G. A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280–283. doi: 10.1038/288280a0. [DOI] [PubMed] [Google Scholar]
  27. Pay G. F., Wallis R. B., Zelaschi D. A metabolite of sulphinpyrazone that is largely responsible for the effect of the drug on the platelet prostaglandin pathway. Biochem Soc Trans. 1980 Dec;8(6):727–728. doi: 10.1042/bst0080727. [DOI] [PubMed] [Google Scholar]
  28. Rainsford K. D., Whitehouse M. W. Are all aspirins really alike? A comparison of gastric ulcerogenicity with bio-efficacy in rats. Pharmacol Res Commun. 1980 Jan;12(1):85–95. doi: 10.1016/s0031-6989(80)80066-x. [DOI] [PubMed] [Google Scholar]
  29. Renwick A. G., Evans S. P., Sweatman T. W., Cumberland J., George C. F. The role of the gut flora in the reduction of sulphinpyrazone in the rat. Biochem Pharmacol. 1982 Aug 15;31(16):2649–2656. doi: 10.1016/0006-2952(82)90713-4. [DOI] [PubMed] [Google Scholar]
  30. Roth S. H. Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. Am J Med. 1987 Oct 30;83(4B):25–30. doi: 10.1016/0002-9343(87)90589-4. [DOI] [PubMed] [Google Scholar]
  31. Rozencweig M., Staquet M., Klastersky J. Antibacterial activity and pharmacokinetics of bacampicillin and ampicillin. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):592–597. doi: 10.1002/cpt1976195part1592. [DOI] [PubMed] [Google Scholar]
  32. Shashoua V. E., Jacob J. N., Ridge R., Campbell A., Baldessarini R. J. Gamma-aminobutyric acid esters. 1. Synthesis, brain uptake, and pharmacological studies of aliphatic and steroid esters of gamma-aminobutyric acid. J Med Chem. 1984 May;27(5):659–664. doi: 10.1021/jm00371a018. [DOI] [PubMed] [Google Scholar]
  33. Smith R. A., Dupe R. J., English P. D., Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature. 1981 Apr 9;290(5806):505–508. doi: 10.1038/290505a0. [DOI] [PubMed] [Google Scholar]
  34. Strong H. A., Oates J., Sembi J., Renwick A. G., George C. F. Role of the gut flora in the reduction of sulfinpyrazone in humans. J Pharmacol Exp Ther. 1984 Sep;230(3):726–732. [PubMed] [Google Scholar]
  35. Strong H. A., Warner N. J., Renwick A. G., George C. F. Sulindac metabolism: the importance of an intact colon. Clin Pharmacol Ther. 1985 Oct;38(4):387–393. doi: 10.1038/clpt.1985.192. [DOI] [PubMed] [Google Scholar]
  36. Swanson B. N., Vlasses P. H., Ferguson R. K., Bergquist P. A., Till A. E., Irvin J. D., Harris K. Influence of food on the bioavailability of enalapril. J Pharm Sci. 1984 Nov;73(11):1655–1657. doi: 10.1002/jps.2600731146. [DOI] [PubMed] [Google Scholar]
  37. Tatsumi K., Kitamura S., Yamada H. Sulfoxide reductase activity of liver aldehyde oxidase. Biochim Biophys Acta. 1983 Sep 14;747(1-2):86–92. doi: 10.1016/0167-4838(83)90125-5. [DOI] [PubMed] [Google Scholar]
  38. Ulm E. H., Hichens M., Gomez H. J., Till A. E., Hand E., Vassil T. C., Biollaz J., Brunner H. R., Schelling J. L. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982 Sep;14(3):357–362. doi: 10.1111/j.1365-2125.1982.tb01991.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Van Lear G. E., Chiccarelli F. S., Bonenfant P. A., Barr A. Quantitation of the anti-inflammatory agent fenbufen and its metabolites in human serum and urine using high-pressure liquid chromatography. J Pharm Sci. 1978 Dec;67(12):1662–1664. doi: 10.1002/jps.2600671206. [DOI] [PubMed] [Google Scholar]
  40. Welling P. G., Elliott R. L., Pitterle M. E., Corrick-West H. P., Lyons L. L. Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate. J Pharm Sci. 1979 Feb;68(2):150–155. doi: 10.1002/jps.2600680208. [DOI] [PubMed] [Google Scholar]
  41. Wilk S., Mizoguchi H., Orlowski M. gamma-Glutamyl dopa: a kidney-specific dopamine precursor. J Pharmacol Exp Ther. 1978 Jul;206(1):227–232. [PubMed] [Google Scholar]
  42. Wilkinson P. J., Reeves D. S., Wise R., Allen J. T. Volunteer and clinical studies with carfecillin: a new orally administered ester of carbenicillin. Br Med J. 1975 May 3;2(5965):250–252. doi: 10.1136/bmj.2.5965.250. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES